Veru Inc.
VERUVeru Inc. (VERU) is a pharmaceutical company that develops and commercializes specialized medicines primarily for the treatment of men's health, including prostate cancer, benign prostatic hyperplasia, and sexual health. The company also focuses on infectious disease products, including treatments for COVID-19, and has a portfolio that includes both FDA-approved drugs and pipeline candidates. Founded in 1998, Veru aims to address unmet medical needs with innovative therapies.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 7, 2014 | $0.07 | 2014-04-28 | 2014-04-30 |
| February 5, 2014 | $0.07 | 2014-01-27 | 2014-01-29 |
| November 6, 2013 | $0.07 | 2013-10-28 | 2013-10-30 |
| August 7, 2013 | $0.07 | 2013-07-29 | 2013-07-31 |
| May 8, 2013 | $0.07 | 2013-04-29 | 2013-05-01 |
Dividends Summary
- Consistent Payer: Veru Inc. has rewarded shareholders with 18 dividend payments over the past 4 years.
- Total Returned Value: Investors who held VERU shares during this period received a total of $1.04 per share in dividend income.
- Latest Payout: The most recent dividend of $0.07/share was paid 4279 days ago, on May 7, 2014.
- Yield & Schedule: VERU currently pays dividends quarterly with an annual yield of 10.41%.
- Dividend Growth: Since 2010, the dividend payout has grown by 40.0%, from $0.05 to $0.07.
- Dividend Reliability: VERU has maintained or increased its dividend for 18 consecutive payments.
Company News
Veru sells its FC2 Female Condom business for $18 million, reducing its workforce by 90% and refocusing on its biopharma pipeline, including late-stage trials for enobosarm to treat weight loss in GLP-1-treated patients.
Veru Inc. has sold its FC2 Female Condom business for $18 million, allowing the company to focus on its late-stage biopharmaceutical pipeline, including a Phase 2b clinical trial evaluating enobosarm to preserve muscle and augment fat loss in patients receiving the GLP-1 receptor agonist Wegovy.
The sexual wellness market is expected to grow at a CAGR of 4.7% by 2031, driven by increasing awareness of sexual health and the availability of a wide range of products. However, social stigma and regulatory challenges remain as key restraints.
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Th...
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the Ame...
